Literature DB >> 27271752

Novel nuclear hENT2 isoforms regulate cell cycle progression via controlling nucleoside transport and nuclear reservoir.

Natalia Grañé-Boladeras1,2,3, Christopher M Spring4, W J Brad Hanna5, Marçal Pastor-Anglada6,7, Imogen R Coe8.   

Abstract

Nucleosides participate in many cellular processes and are the fundamental building blocks of nucleic acids. Nucleoside transporters translocate nucleosides across plasma membranes although the mechanism by which nucleos(t)ides are translocated into the nucleus during DNA replication is unknown. Here, we identify two novel functional splice variants of equilibrative nucleoside transporter 2 (ENT2), which are present at the nuclear envelope. Under proliferative conditions, these splice variants are up-regulated and recruit wild-type ENT2 to the nuclear envelope to translocate nucleosides into the nucleus for incorporation into DNA during replication. Reduced presence of hENT2 splice variants resulted in a dramatic decrease in cell proliferation and dysregulation of cell cycle due to a lower incorporation of nucleotides into DNA. Our findings support a novel model of nucleoside compartmentalisation at the nuclear envelope and translocation into the nucleus through hENT2 and its variants, which are essential for effective DNA synthesis and cell proliferation.

Entities:  

Keywords:  Cell cycle regulation; DNA synthesis; ENT2; HNP36; Nucleoside metabolism; Nucleoside transporters; SLC29A2

Mesh:

Substances:

Year:  2016        PMID: 27271752     DOI: 10.1007/s00018-016-2288-9

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  78 in total

1.  Heterodimerization with Its splice variant blocks the ghrelin receptor 1a in a non-signaling conformation: a study with a purified heterodimer assembled into lipid discs.

Authors:  Sophie Mary; Jean-Alain Fehrentz; Marjorie Damian; Gérald Gaibelet; Hélène Orcel; Pascal Verdié; Bernard Mouillac; Jean Martinez; Jacky Marie; Jean-Louis Banères
Journal:  J Biol Chem       Date:  2013-07-09       Impact factor: 5.157

2.  Mitogen-activated protein kinase phosphorylation of splicing factor 45 (SPF45) regulates SPF45 alternative splicing site utilization, proliferation, and cell adhesion.

Authors:  Adnan M Al-Ayoubi; Hui Zheng; Yuying Liu; Tao Bai; Scott T Eblen
Journal:  Mol Cell Biol       Date:  2012-05-21       Impact factor: 4.272

3.  Functional production and reconstitution of the human equilibrative nucleoside transporter (hENT1) in Saccharomyces cerevisiae. Interaction of inhibitors of nucleoside transport with recombinant hENT1 and a glycosylation-defective derivative (hENT1/N48Q).

Authors:  M F Vickers; R S Mani; M Sundaram; D L Hogue; J D Young; S A Baldwin; C E Cass
Journal:  Biochem J       Date:  1999-04-01       Impact factor: 3.857

4.  Dominant negative effects of a non-conducting TREK1 splice variant expressed in brain.

Authors:  Emma L Veale; Kathryn A Rees; Alistair Mathie; Stefan Trapp
Journal:  J Biol Chem       Date:  2010-07-06       Impact factor: 5.157

5.  Overlapping high-resolution copy number alterations in cancer genomes identified putative cancer genes in hepatocellular carcinoma.

Authors:  Chian-Feng Chen; En-Chi Hsu; Kuen-Tyng Lin; Pang-Hsien Tu; Hung-Wei Chang; Chin-Hui Lin; Yann-Jang Chen; De-Leung Gu; Chi-Hung Lin; Jer-Yuarn Wu; Yuan-Tsong Chen; Ming-Ta Hsu; Yuh-Shan Jou
Journal:  Hepatology       Date:  2010-11       Impact factor: 17.425

6.  Merging high-quality biochemical fractionation with a refined flow cytometry approach to monitor nucleocytoplasmic protein expression throughout the unperturbed mammalian cell cycle.

Authors:  Margit Rosner; Katharina Schipany; Markus Hengstschläger
Journal:  Nat Protoc       Date:  2013-02-28       Impact factor: 13.491

Review 7.  Control of nucleotide pools in mammalian cells.

Authors:  G Bjursell; L Skoog
Journal:  Antibiot Chemother (1971)       Date:  1980

Review 8.  Molecular biology and regulation of nucleoside and nucleobase transporter proteins in eukaryotes and prokaryotes.

Authors:  Miguel A Cabrita; Stephen A Baldwin; James D Young; Carol E Cass
Journal:  Biochem Cell Biol       Date:  2002       Impact factor: 3.626

Review 9.  The human concentrative and equilibrative nucleoside transporter families, SLC28 and SLC29.

Authors:  James D Young; Sylvia Y M Yao; Jocelyn M Baldwin; Carol E Cass; Stephen A Baldwin
Journal:  Mol Aspects Med       Date:  2013 Apr-Jun

Review 10.  Nucleotide- and nucleoside-converting ectoenzymes: Important modulators of purinergic signalling cascade.

Authors:  Gennady G Yegutkin
Journal:  Biochim Biophys Acta       Date:  2008-02-12
View more
  7 in total

1.  Generation of a hTERT-Immortalized Human Sertoli Cell Model to Study Transporter Dynamics at the Blood-Testis Barrier.

Authors:  Raymond K Hau; Siennah R Miller; Stephen H Wright; Nathan J Cherrington
Journal:  Pharmaceutics       Date:  2020-10-22       Impact factor: 6.321

Review 2.  A guide to plasma membrane solute carrier proteins.

Authors:  Mattia D Pizzagalli; Ariel Bensimon; Giulio Superti-Furga
Journal:  FEBS J       Date:  2020-09-18       Impact factor: 5.542

3.  Emerging Roles of Nucleoside Transporters.

Authors:  Marçal Pastor-Anglada; Sandra Pérez-Torras
Journal:  Front Pharmacol       Date:  2018-06-06       Impact factor: 5.810

Review 4.  Equilibrative Nucleoside Transporter 2: Properties and Physiological Roles.

Authors:  Safaa M Naes; Sharaniza Ab-Rahim; Musalmah Mazlan; Amirah Abdul Rahman
Journal:  Biomed Res Int       Date:  2020-12-03       Impact factor: 3.411

Review 5.  Re-Discovery of Pyrimidine Salvage as Target in Cancer Therapy.

Authors:  Melanie Walter; Patrick Herr
Journal:  Cells       Date:  2022-02-20       Impact factor: 6.600

Review 6.  Inborn Errors of Nucleoside Transporter (NT)-Encoding Genes (SLC28 and SLC29).

Authors:  Marçal Pastor-Anglada; Aida Mata-Ventosa; Sandra Pérez-Torras
Journal:  Int J Mol Sci       Date:  2022-08-07       Impact factor: 6.208

Review 7.  Who Is Who in Adenosine Transport.

Authors:  Marçal Pastor-Anglada; Sandra Pérez-Torras
Journal:  Front Pharmacol       Date:  2018-06-14       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.